Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-25
2011-01-25
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S235500, C514S318000, C514S333000, C514S343000, C546S300000, C546S261000, C546S194000, C546S276400, C546S256000, C544S131000
Reexamination Certificate
active
07875633
ABSTRACT:
A compound represented by the formula (I) is contained as an active ingredient:wherein R1and R2independently represent a hydrogen atom, a lower alkyl group or the like, or R1together with a nitrogen atom to which L, Z2and R1are attached may form an aliphatic nitrogenated heterocyclic group and R1and R2together with a nitrogen atom to which they are attached may form an aliphatic nitrogenated heterocyclic group; X represents a methine group or a nitrogen atom; Y represents —CH2—O—, —CH═CH— or the like; Z1represents a single bond, a C1-4alkylene group or the like; Z2represents a single bond or a C1-4alkylene group; L represents a methylene group, a C3-8cycloalkylene group or the like; and Ar represents an aromatic carbocyclic group or the like. The compound is useful as a pharmaceutical for a central nerves system disease, a cardiovascular disease or a metabolic disease.
REFERENCES:
patent: 7067540 (2006-06-01), Devadas et al.
patent: 2004/0077628 (2004-04-01), Ishihara et al.
patent: 2005/0049253 (2005-03-01), Tegley
patent: 2005/0209274 (2005-09-01), Lynch et al.
patent: 2006/0106046 (2006-05-01), Moriya et al.
patent: 2006/0287340 (2006-12-01), Moriya et al.
patent: 2007/0208046 (2007-09-01), Otake et al.
patent: 2007/0249659 (2007-10-01), Sakuraba et al.
patent: 2007/0299070 (2007-12-01), Suzuki et al.
patent: 1 285 651 (2003-02-01), None
patent: 1 741 703 (2007-10-01), None
patent: 1 876 179 (2008-01-01), None
patent: WO 01/21577 (2001-03-01), None
patent: WO 01/21577 (2001-03-01), None
patent: WO 02/02744 (2002-01-01), None
patent: WO 02/02744 (2002-01-01), None
patent: WO 02/06245 (2002-01-01), None
patent: WO 02/081454 (2002-10-01), None
patent: WO 03/068230 (2003-08-01), None
patent: WO 2005/018557 (2005-03-01), None
patent: WO 2005/018557 (2005-03-01), None
patent: WO 2005/047293 (2005-05-01), None
patent: WO 2006/018117 (2006-02-01), None
patent: WO 2007/011284 (2007-01-01), None
Bost. F. et al., “The role of MAPKs in adipocyte differentiation and obesity”, Biochimie, vol. 87, pp. 51-56, 2005.
Browning, A., “Recent developments in the discovery of melanin-concentrating hormone antagonists: novel antiobesity agents”, Expert Opinion Tkher. Patents, vol. 14, No. 3, pp. 313-325, 2004.
Carpenter, A. J. et al., “Melanin-concentrating hormone receptor antagonists as potential antiobesity agents”, Expert Opin. Ther. Patents, vol. 12, No. 11, pp. 1639-1646, 2002.
Dyke, H. J. et al., “Recent developments in the discovery of MCH-1R antagonists for the treatment of obesity—an update”, Expert Opin. Ther. Patents, vol. 15, No. 10, pp. 1303-1313, 2005.
Haga Yuji
Naya Akira
Otake Norikazu
Sakamoto Toshihiro
Banyu Pharmaceutical Co. Ltd.
Fair Janet E.
Javanmard Sahar
Padmanabhan Sreeni
Todaro John C.
LandOfFree
Phenylpyridone derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenylpyridone derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenylpyridone derivative will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2672031